<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655274</url>
  </required_header>
  <id_info>
    <org_study_id>2020-11</org_study_id>
    <nct_id>NCT04655274</nct_id>
  </id_info>
  <brief_title>Comparision of Visual Outcomes and Patient Satisfaction Between Two Diffractive Trifocal Intraocular Lenses</brief_title>
  <official_title>Comparision of Visual Outcomes and Patient Satisfaction Between Two Diffractive Trifocal Intraocular Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akdeniz University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akdeniz University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study was to compare the clinical outcomes such as visual&#xD;
      function, refraction errors and visual quality of patients undergoing cataract surgery with&#xD;
      implantation of two different models of diffractive trifocal IOLs: RayOne Trifocal (Rayner&#xD;
      IOL, Ltd.) and AcrySof IQ PanOptix (Alcon Laboratories, Inc.) IOL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cataract is affecting over 95 million people worldwide and remains the leading cause of&#xD;
      vision impairment and blindness. Cataract surgery is an effective method for restoring visual&#xD;
      acuity (VA). With the advancement of cataract surgery technique and intraocular lenses (IOL)&#xD;
      technologies, expectations of patients from cataract surgery have good vision at distance and&#xD;
      near ranges without using spectacles. The standard IOLs design were monofocal, which offered&#xD;
      only fixed focal distance. One of the main factors for dissatisfaction after monofocal&#xD;
      pseudophakic eyes is lack of accommodation. Previous studies demonstrated that this problem&#xD;
      can be resolved by using diffractive trifocal IOLs. Diffractive trifocal IOLs provide&#xD;
      effective near, intermediate and distance visual restoration, and has been widely used in&#xD;
      patients who want to achieve spectacle independence after surgery. However, some possible&#xD;
      optical side effects of trifocal IOLs have been reported, including halos and other&#xD;
      dysphotopsias, reduced contrast sensitivity (CS), glare disability, which can significantly&#xD;
      affect visual quality and patient satisfaction. The purpose of the present study was to&#xD;
      compare the clinical outcomes such as visual function, refraction errors and visual quality&#xD;
      of patients undergoing cataract surgery with implantation of two different models of&#xD;
      diffractive trifocal IOLs: RayOne Trifocal (Rayner IOL, Ltd.) and AcrySof IQ PanOptix (Alcon&#xD;
      Laboratories, Inc.) IOL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Actual">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Quality of Vision score</measure>
    <time_frame>3 months</time_frame>
    <description>Glare, halos, starbursts, hazy/blurred/double vision, distortion, focusing difficulties, fluctuation, and depth perception</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Cataract Senile</condition>
  <arm_group>
    <arm_group_label>RayOne Trifocal intraocular lenses</arm_group_label>
    <description>Eyes of patients undergoing cataract surgery with implantation of RayOne Trifocal (Rayner IOL, Ltd.) intraocular lenses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AcrySof IQ PanOptix intraocular lenses</arm_group_label>
    <description>Eyes of patients undergoing cataract surgery with implantation of AcrySof IQ PanOptix (Alcon Laboratories, Inc.) intraocular lenses</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>The Quality of Vision questionnaire</intervention_name>
    <description>The Quality of Vision questionnaire rates glare, halos, starbursts, hazy/blurred/double vision, distortion, focusing difficulties, fluctuation, and depth perception conditions.</description>
    <arm_group_label>AcrySof IQ PanOptix intraocular lenses</arm_group_label>
    <arm_group_label>RayOne Trifocal intraocular lenses</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients underwent cataract surgery with trifocal intraocular lenses implantation in one or&#xD;
        both eyes at Akdeniz University Hospital Ophtalmology Department.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients underwent cataract surgery with trifocal intraocular lenses implantation in&#xD;
             one or both eyes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Amblyopia&#xD;
&#xD;
          -  Axial length (AL) over 25 mm&#xD;
&#xD;
          -  Previous history of corneal or refractive surgery&#xD;
&#xD;
          -  Ocular comorbidity (corneal scars, keratoconus, and corneal endothelial dystrophy,&#xD;
             chronic or recurrent uveitis, macular degeneration, diabetes mellitus with retinal&#xD;
             changes, glaucoma or intraocular pressure equal or higher than 24 mmHg)&#xD;
&#xD;
          -  Patient inability to understand and/or fill in patient questionnaires&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Aslı Çentinkaya Yaprak</name>
      <address>
        <city>Antalya</city>
        <zip>070059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Akdeniz University</investigator_affiliation>
    <investigator_full_name>Aslı Çetinkaya Yaprak</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

